Clinical Trials Logo

Head and Neck Neoplasms clinical trials

View clinical trials related to Head and Neck Neoplasms.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 21

NCT ID: NCT00003327 Active, not recruiting - Clinical trials for Head and Neck Cancer

Paclitaxel in Treating Patients With Recurrent or Refractory Head and Neck Cancer

Start date: September 1997
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of paclitaxel in treating patients with recurrent or refractory head and neck cancer.

NCT ID: NCT00003257 Active, not recruiting - Clinical trials for Head and Neck Cancer

Gene Therapy in Treating Patients With Recurrent Head and Neck Cancer

Start date: January 1998
Phase: Phase 2
Study type: Interventional

RATIONALE: Inserting the gene for p53 into a person's tumor may improve the body's ability to fight cancer or make the cancer more sensitive to chemotherapy. PURPOSE: Phase II trial to study the effectiveness of gene therapy in treating patients who have recurrent head and neck cancer.

NCT ID: NCT00003251 Active, not recruiting - Clinical trials for Head and Neck Cancer

Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer

Start date: December 1997
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses x-rays to damage tumor cells. Drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy and radiation therapy. PURPOSE: Phase I/II trial to study the effectiveness of amifostine plus cisplatin, paclitaxel, and radiation therapy in treating patients who have advanced unresectable head and neck cancer.

NCT ID: NCT00003182 Active, not recruiting - Clinical trials for Head and Neck Cancer

Cisplatin and Gemcitabine in Treating Patients With Advanced Squamous Cell Cancer of the Head and Neck

Start date: March 1997
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of cisplatin and gemcitabine in treating patients with advanced squamous cell cancer of the head and neck that cannot be surgically removed.

NCT ID: NCT00002747 Active, not recruiting - Clinical trials for Head and Neck Cancer

Surgery and Radiation Therapy With or Without Chemotherapy in Treating Patients With Mouth Cancer

Start date: September 1992
Phase: Phase 3
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known if surgery plus radiation therapy is more effective with or without chemotherapy for treating mouth cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of surgery and radiation therapy with or without chemotherapy in treating patients with stage II, stage III, or stage IV mouth cancer.

NCT ID: NCT00002659 Active, not recruiting - Clinical trials for Head and Neck Cancer

Cisplatin Plus Epinephrine in Treating Patients With Recurrent or Refractory Head and Neck Cancer

Start date: May 1995
Phase: Phase 3
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known if treatment with cisplatin plus epinephrine is effective for head and neck cancer. PURPOSE: Randomized double-blinded phase III trial to determine the effectiveness of cisplatin plus epinephrine in injectable gel form in treating patients who have recurrent or refractory head and neck cancer.